Achuthan Aruljothy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Achuthan Aruljothy has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Neeraj Narula
Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
2 shared publications Abdul‐Aziz Alshahrani
Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute McMaster University Hamilton ON Canada
1 shared publicationBritt Christensen
Inflammatory Bowel Disease Center University of Chicago Medicine Chicago IL USA
1 shared publication- Cara Pray
Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre , Hamilton, ON
1 shared publication - David T. Rubin
University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL 60637
1 shared publication - Emily Chu Lee Wong
Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
1 shared publication
Latest Publications
- 30 September 2022
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 29 (8) , 1263-1271
Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn’s Disease: A Post Hoc Analysis
Background: We evaluated whether postinduction ulcer size and patient-reported outcome (PRO) severity are associated with the achievement of 1-year endoscopic remission (ER) in patients with Crohn’s disease (CD). Methods: This post hoc analysis combined data from several clinical trials including 283 patients with baseline ulcers ≥5 mm with repeat endoscopy after ustekinumab or adalimumab induction therapy. Patient-reported outcomes including stool frequency (SF) and abdominal pain (AP) were measured by the Crohn’s Disease Activity Index. Thresholds of SF ≥4 and/or AP ≥2 indicated moderately to severely active CD. Endoscopic remission was defined as Simple Endoscopic Score for CD (SES-CD) <3. Multivariate logistic regression models adjusted for confounders (including disease duration and treatment allocation) evaluated the relationships between postinduction ulcer size, PRO symptoms, and achievement of 1-year ER. Results: Among the 131 CD patients who continued to have ulcers ≥5 mm after induction therapy, 48 (36.6%) achieved 1-year ER. Patients with postinduction ulcers ≥5 mm were approximately 5 times less likely to achieve 1-year ER than the 152 individuals who had small or no postinduction ulcers (odds ratio [OR], 0.20; 95% CI, 0.08-0.51, P = .001). In patients with ulcers ≥5 mm after induction, postinduction PRO scores (including PRO2 and PRO3) did not predict 1-year ER. Conclusions: Crohn’s disease patients with ulcers ≥5 mm after induction therapy are less likely to achieve 1-year ER. Postinduction PRO severity does not offer additional prognostic information. This may suggest that objective measures of disease such as endoscopic ulcer size should be considered over symptom assessments for determining clinical response to therapy and utilized in trials for maintenance therapy.
- 30 September 2022
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 29 (8) , 1263-1271
Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn’s Disease: A Post Hoc Analysis
Background: We evaluated whether postinduction ulcer size and patient-reported outcome (PRO) severity are associated with the achievement of 1-year endoscopic remission (ER) in patients with Crohn’s disease (CD). Methods: This post hoc analysis combined data from several clinical trials including 283 patients with baseline ulcers ≥5 mm with repeat endoscopy after ustekinumab or adalimumab induction therapy. Patient-reported outcomes including stool frequency (SF) and abdominal pain (AP) were measured by the Crohn’s Disease Activity Index. Thresholds of SF ≥4 and/or AP ≥2 indicated moderately to severely active CD. Endoscopic remission was defined as Simple Endoscopic Score for CD (SES-CD) <3. Multivariate logistic regression models adjusted for confounders (including disease duration and treatment allocation) evaluated the relationships between postinduction ulcer size, PRO symptoms, and achievement of 1-year ER. Results: Among the 131 CD patients who continued to have ulcers ≥5 mm after induction therapy, 48 (36.6%) achieved 1-year ER. Patients with postinduction ulcers ≥5 mm were approximately 5 times less likely to achieve 1-year ER than the 152 individuals who had small or no postinduction ulcers (odds ratio [OR], 0.20; 95% CI, 0.08-0.51, P = .001). In patients with ulcers ≥5 mm after induction, postinduction PRO scores (including PRO2 and PRO3) did not predict 1-year ER. Conclusions: Crohn’s disease patients with ulcers ≥5 mm after induction therapy are less likely to achieve 1-year ER. Postinduction PRO severity does not offer additional prognostic information. This may suggest that objective measures of disease such as endoscopic ulcer size should be considered over symptom assessments for determining clinical response to therapy and utilized in trials for maintenance therapy.
- 1 November 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (11-12) , 1676-1682
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission
Summary: Background: Histologic remission in ulcerative colitis (UC) patients may be associated with positive outcomes. It is unclear whether UC patients in endoscopic remission obtain additional benefit from achieving histologic remission.Aim: To evaluate the relationship between time to relapse and histological activity among UC patients in endoscopic remission.Methods: In this retrospective study using an observational database, we identified UC patients who had achieved endoscopic remission (Mayo endoscopic subscore 0). Index colonoscopy was the first colonoscopy when endoscopic remission was achieved. Histologic activity was classified as normal, inactive or active colitis. The primary outcome was time to relapse. Secondary outcomes included reasons for relapse and the association between baseline variables and risk of relapse. A Cox proportional hazards model evaluated baseline factors and the outcome of relapse.Results: We included 269 patients. The Kaplan‐Meier survival curve showed no significant difference between the presence or absence of histologic activity and time to relapse (log rank P = 0.85). There was no difference in time to clinical relapse of patients with histologically active colitis compared to inactive colitis (adjusted hazard ratio [AHR] 1.17, 95% CI 0.58‐2.32, P = 0.67]). 5‐aminosalicylate use (AHR 0.42, 95% CI 0.21‐0.82, P = 0.011), pancolitis (AHR 0.32, 95% CI 0.13‐0.75, P = 0.008), left‐sided colitis (AHR 0.46; 95% CI 0.22‐0.98; P = 0.044) and older age (AHR 0.96, 95% CI 0.94‐0.99, P = 0.002) were significantly associated with reduced time to clinical relapse.Conclusion: Histologic remission did not influence time to relapse in UC patients who had achieved endoscopic remission.
- 1 November 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (11-12) , 1676-1682
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission
Summary: Background: Histologic remission in ulcerative colitis (UC) patients may be associated with positive outcomes. It is unclear whether UC patients in endoscopic remission obtain additional benefit from achieving histologic remission.Aim: To evaluate the relationship between time to relapse and histological activity among UC patients in endoscopic remission.Methods: In this retrospective study using an observational database, we identified UC patients who had achieved endoscopic remission (Mayo endoscopic subscore 0). Index colonoscopy was the first colonoscopy when endoscopic remission was achieved. Histologic activity was classified as normal, inactive or active colitis. The primary outcome was time to relapse. Secondary outcomes included reasons for relapse and the association between baseline variables and risk of relapse. A Cox proportional hazards model evaluated baseline factors and the outcome of relapse.Results: We included 269 patients. The Kaplan‐Meier survival curve showed no significant difference between the presence or absence of histologic activity and time to relapse (log rank P = 0.85). There was no difference in time to clinical relapse of patients with histologically active colitis compared to inactive colitis (adjusted hazard ratio [AHR] 1.17, 95% CI 0.58‐2.32, P = 0.67]). 5‐aminosalicylate use (AHR 0.42, 95% CI 0.21‐0.82, P = 0.011), pancolitis (AHR 0.32, 95% CI 0.13‐0.75, P = 0.008), left‐sided colitis (AHR 0.46; 95% CI 0.22‐0.98; P = 0.044) and older age (AHR 0.96, 95% CI 0.94‐0.99, P = 0.002) were significantly associated with reduced time to clinical relapse.Conclusion: Histologic remission did not influence time to relapse in UC patients who had achieved endoscopic remission.